


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: J. Yuan, L. Yang, P. Mao and L. Qu, *RSC Adv.*, 2016, DOI: 10.1039/C6RA19002B.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

Silver-catalyzed synthesis of 2-arylvinylphosphonates by cross-coupling of β -nitrostyrenes with *H*-phosphites

Jin-Wei Yuan,* Liang-Ru Yang, Pu Mao, and Ling-Bo Qu*

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

An efficient protocol for stereoselective synthesis of 2-arylvinylphosphonates has been developed via AgNO_3 -catalyzed cross-coupling of β -nitrostyrenes with dialkyl *H*-phosphites under mild conditions. With losing nitro group of β -nitrostyrenes, the reaction proceeds smoothly and could provide the desired products with moderate to good yield.


Introduction

Vinylphosphonates are important molecules known for their interesting properties spanning across chemistry as well as biology.¹ They are suitable substrates for various name reactions such as Michael additions, cycloaddition, and Horner-Wadsworth-Emmons reactions.² They have been also extensively used in polymer sciences as additives or flame-retardants.³ In medical chemistry, vinylphosphonates often exhibit interesting biological properties such as antiviral, antibacterial, anticancer implications.⁴ For these reasons, the development of simple and stereoselective methods to prepare vinylphosphonates has become important in organic synthesis.


In recent years, a wide variety of transition metal catalyzed cross-coupling reactions for the construction of C–P bond have been developed.⁵ As a significant motif in organic chemistry, the alkenyl C_{sp^2} –P bond formation has attracted much attention. There are two main strategies applicable in forming the alkenyl C_{sp^2} –P bond: the phosphorylation of alkynes or terminal alkynes, and functionalized alkenes. Dialkyl *H*-phosphites are coupled with functionalized alkenes including styrene, 2,2-dibromostyrenes, alkenyl acids, vinylidonium tetrafluoroborates to form 2-arylvinylphosphonates using Cu as a catalyst.⁶ Transition-metals such as Ni, and Ni/Zn-catalyzed reactions of alkenyl acids, 2,2-dibromostyrenes with dialkyl phosphites have been reported.⁷ In 2015, Zou has described that Mn(III)-mediated alkenyl $\text{C}(\text{sp}^2)$ –P bond formation from the reaction of 2-nitrostyrenes with dialkyl phosphites, and Tan found an efficient Ag-catalyzed reaction of styrenes with dialkyl phosphites using $\text{K}_2\text{S}_2\text{O}_8$ as the oxidant, and TEMPO as the additive⁸ (Scheme 1, a). Transition metals such as Zr/Cu, Pd and Rh catalysts were employed for the reaction of terminal alkynes with Dialkyl *H*-phosphites and dialkyl chlorophosphates (Scheme 1, b).⁹ It has also

been reported that trialkyl phosphates react with 1-bromoalkenes and vinylboronate esters catalyzed by transition metal Pd, and Cu (Scheme 1, c).¹⁰ Moreover, 2-arylvinylphosphonates are formed by the Mizoroki-Heck reaction of arylboronic acids with dialkyl vinylphosphonates catalyzed by $\text{Pd}(\text{OAc})_2$, and via nucleophilic substitution of benzyl bromides with Bestmann-Ohira reagents.¹¹ Although these approaches are available for the synthesis of 2-arylvinylphosphonates, most of them suffer from several drawbacks such as lack of stereoselectivity (a mixture of *E/Z* products), the need to use a rather expensive catalyst, drastic conditions being not compatible with molecules containing sensitive functional groups. As a result, there is still a strong need for alternative methods that would allow the stereoselective synthesis of 2-arylvinylphosphonates from readily available starting materials and catalysts under mild reaction conditions.

Previous works:



This work:



Scheme 1 Strategies for synthesis of 2-arylvinylphosphonates

(*E*)- β -Nitrostyrenes are useful intermediates in organic synthesis and are important structural units that can be used

School of Chemistry and Chemical Engineering, Henan University of Technology; Academician Workstation for Natural Medicinal Chemistry of Henan Province, Zhengzhou 450001, P.R. China. E-mail: yuanjinweigs@126.com, Fax: +86-371-67756718; Tel: +86-371-67756718

† Electronic Supplementary Information (ESI) available. Part of the experimental detail and NMR spectra data See DOI: 10.1039/x0xx00000x

as starting material for many classes of compounds.¹² In general, the nitro group activates α - and/or β -position of a substrate, and in the reaction the nitro group is either remaining or leaving.¹³ (*E*)- β -Nitrostyrenes are good radical acceptors and react with alkyl radicals from different sources to generate (*E*)-alkenes under a variety of conditions and the reaction mechanism appears to involve a free-radical addition-elimination reaction.¹⁴ Although Zou has described that 2-arylvinylphosphonates could be synthesized by Mn(III)-catalyzed reaction of 2-nitrostyrenes with dialkyl phosphites,^{8a} and Tan has found that Ag-catalyzed reaction of styrenes with dialkyl phosphites,^{8b} these methodologies need use expensive and unstable catalysts, acid circumstance, strong oxidants, or with low yield. Drawing inspiration from recent studies¹⁵ that dialkyl phosphites could be utilized as a phosphoryl radical precursor,¹⁶ we wonder that 2-arylvinylphosphonates can be synthesized by cross-coupling of β -nitrostyrenes with dialkyl *H*-phosphites. Herein, we describe a new silver-catalyzed cross-coupling reaction between readily available β -nitrostyrenes with dialkyl *H*-phosphites, leading to 2-arylvinylphosphonates in moderate to excellent yields. Some notable features of this protocol are high efficiency, wide functional group tolerance, readily available and stable β -nitrostyrenes with dialkyl *H*-phosphites as starting materials, no oxidants and high stereoselectivity (**Scheme 1**, d).


Results and discussion

Our previous studies showed that the phosphoryl radicals could be easily generated from *H*-phosphites with a catalytic amount of silver salts.¹⁶ Based on this achievement, the model reaction of (*E*)- β -nitrostyrenes (**1a**) and diisopropyl *H*-phosphite (**2a**) was carried out in the presence of AgNO₃ (0.1 eq) in CH₃CN at 90 °C for 20 min. Much to our delight, the desired product (**3a**) was indeed obtained, and the isolated yield was 56% (Table 1, entry 1). The *E* or *Z* stereochemistry of **3a** is easily established by the ¹H NMR analysis. Indeed, the report in the literature has shown that the chemistry shift of β -H proton is 6.10-6.30 ppm with a coupling constant 17.0 Hz typical of *trans* positioned protons, while that of *cis* isomer gives 5.60-5.80 ppm with a coupling constant 15.0 Hz.^{9a} The β -proton of **3a** at δ_{H} =6.27 ppm appears as a triplet with a coupling constant, *J* = 17.6 Hz, which proves that configuration of **3a** is an *E* stereoisomer.

To achieve the optimal conditions, a variety of reaction conditions were employed. Initial screening of different solvents including H₂O, dioxane, CH₃OH, DMSO, DCE and THF were applied instead of CH₃CN. The result revealed that solvents such as H₂O and CH₃OH are not suitable for this reaction, and CH₃CN was clearly the best choice (**Table 1**, entries 1-7). The ratio of substrates (*E*)- β -nitrostyrenes and diisopropyl *H*-phosphite was investigated, and the ratio of 1 : 1.5 could provide the best result (**Table S1**, ESI). The screening of the amount of the catalyst AgNO₃ showed that a good yield (60%) of the product **3a** was obtained when 0.15 equiv of AgNO₃ was employed, and excessive or less amount of the catalyst caused decreased yield (**Table 1**, entries 1, 8-10).

Furthermore, various reaction temperatures were investigated, and increasing the temperature from 40 to 100 °C could enhance the reaction efficacy, and a good yield of 56% could be obtained at 90 °C (**Table 1**, entries 1, 11-14). Based on these

Table 1 Optimization of reaction conditions^a





| Entry | Oxidant (eq.) | Solvent | Temp (°C) | Time (min) | Yield ^b (%) |
|-------|--|-------------------------|-----------|--------------|------------------------|
| 1 | AgNO ₃ (0.1) | CH ₃ CN | 90 | 20 | 56 |
| 2 | AgNO ₃ (0.1) | H ₂ O | 90 | 20 | <5 |
| 3 | AgNO ₃ (0.1) | Dioxane | 90 | 20 | 0 |
| 4 | AgNO ₃ (0.1) | CH ₃ OH | 90 | 20 | 40 |
| 5 | AgNO ₃ (0.1) | DMSO | 90 | 20 | <5 |
| 6 | AgNO ₃ (0.1) | DCE | 90 | 20 | 54 |
| 7 | AgNO ₃ (0.1) | THF | 90 | 20 | 30 |
| 8 | AgNO ₃ (0.05) | CH ₃ CN | 90 | 20 | 45 |
| 9 | AgNO ₃ (0.15) | CH ₃ CN | 90 | 20 | 60 |
| 10 | AgNO ₃ (0.2) | CH ₃ CN | 90 | 20 | 55 |
| 11 | AgNO ₃ (0.15) | CH ₃ CN | 40 | 20 | trace |
| 12 | AgNO ₃ (0.15) | CH ₃ CN | 60 | 20 | 44 |
| 13 | AgNO ₃ (0.15) | CH ₃ CN | 80 | 20 | 49 |
| 14 | AgNO ₃ (0.15) | CH ₃ CN | 100 | 20 | 55 |
| 15 | AgOTf (0.15) | CH ₃ CN | 90 | 20 | <5 |
| 16 | Ag ₂ CO ₃ (0.15) | CH ₃ CN | 90 | 20 | <5 |
| 17 | AgNO ₃ (0.15) | CH ₃ CN | 90 | 40 | 65 |
| 18 | AgNO ₃ (0.15) | CH ₃ CN | 90 | 1.0 h | 70 |
| 19 | AgNO₃ (0.15) | CH₃CN | 90 | 2.0 h | 78 |
| 20 | AgNO ₃ (0.15) | CH ₃ CN | 90 | 3.0 h | 76 |
| 21 | – | CH ₃ CN | 90 | 1.0 h | nr ^c |

^a Reaction conditions: (*E*)- β -nitrostyrene **1a** (0.3 mmol, 44.7 mg), diisopropyl *H*-phosphite **2a** (0.45 mmol, 74.7 mg), AgNO₃ as the catalyst in solvent (3.0 mL).

^b Isolated yield.

^c nr = no reaction.

joyful results, various catalysts of silver salts such as AgOTf and Ag₂CO₃ were further investigated. It was found that they proved to be less effective compared with AgNO₃ (**Table 1**, entries 1, 15 and 16). In addition, various reaction times were also examined. The yield of **3a** dramatically increased if the reaction time was increased, 2.0 h was found to be appropriate choice and the yield was 78% (**Table 1**, entries 1, 17-20). In the absence of AgNO₃, the desired product **3a** was not produced, which indicated that AgNO₃ as a catalyst played an important role in this transformation (**Table 1**, entry 21).

Table 2 Synthesis of 2-arylvinylphosphonates from β -nitrostyrenes with dialkyl *H*-phosphites^{a,b}


^a Reaction conditions: (*E*)- β -nitrostyrenes **1** (0.3 mmol), dialkyl *H*-phosphites **2** (0.45 mmol), AgNO_3 (0.045 mmol, 7.6 mg), in CH_3CN (3.0 mL) at 90°C for 2.0 h.

^b Isolated yields.

With the optimized conditions in hand, we next set out to examine the scope of β -nitrostyrenes and *H*-phosphites, and


the results are summarized in **Table 2**. A range of β -nitrostyrene derivatives were found to undergo denitration phosphonation in good to excellent yields ranging from 48–91% with high stereoselectivity (**Table 2**, entries **3a–3l**, **3m–3zz**). Substituents such as methyl, methoxy, methylenedioxy, fluoro, chloro, bromo, and iodo groups are well tolerated on the aromatic ring and their reactions afforded the target products in good to excellent yields, showing the broad scope of this reaction. β -Nitrostyrenes with electron-donating groups (**Table 2**, entries **3b–3e**) could give slightly better yields than analogues with electron-withdrawing groups (**Table 2**, entries **3f–3j**). The results indicated that electron-donating groups on the phenyl ring contributed to β -position carbon electron density, which made it more susceptible to an electrophilic attack by the phosphonyl radical. Notably, sterically demanding substrates like (*E*)-3,4-dimethoxy- β -nitrostyrenes and (*E*)-2,6-dichloro- β -nitrostyrenes could be phosphorylated in 91% and 70% yields (**Table 2**, entries **3d** and **3g**). However, steric hindrance will lead to lower yield when β -methyl- β -nitrostyrene is employed (**Table 2**, entry **3l**). It was gratifying to find that heterocyclic β -nitroalkene ((*E*)-2-(2-nitrovinyl)thiophene) also reacted smoothly with diisopropyl *H*-phosphite, leading to the corresponding product **3k** in moderated yield (65%). Unfortunately, aliphatic nitroalkenes failed to deliver the desired products with the current catalytic system.

Subsequently, the scope for various dialkyl *H*-phosphites was also investigated. The reaction could proceed smoothly using different dialkyl *H*-phosphites to form the desired products in moderate to excellent yields in 60–78% with high stereoselectivity (**Table 2**, entries **3a**, **3m–3q**). It is gratifying to see that the reaction not only worked with dialkyl *H*-phosphites but also with diphenylphosphine oxide as well (**Table 2**, entry **3r**). Using the standard reaction condition, the corresponding products were produced in moderate to good yields (**Table 2**, entries **3s–3zz**). However, the yields of products **3y** and **3z** were lower when dibenzyl *H*-phosphite was employed, which was possible that partial product was hydrolyzed. Bisphosphonate drugs are used to treat a variety of bone resorption diseases, such as osteoporosis, Paget's disease, and hypercalcemia due to malignancy.¹⁷ In the study of using (*E*)-5-(2-nitrovinyl)benzo[*d*][1,3]dioxole and diethyl *H*-phosphite as the coupling partners, we found that this resulted in a mixture of mono- **3w** (yield: 50%) and bis-phosphorylated products **3w'** (yield: 24%) when 3.0 eq. diethyl *H*-phosphite was employed at 90°C for 10 h (**Scheme 2**).




Scheme 2 Synthesis of mono- and bis-phosphorylated products

To clarify the reaction mechanism, some controlled experiments were designed to investigate this transformation (**Scheme 3**). When the reaction of (*E*)- β -nitrostyrene **1a** with diisopropyl *H*-phosphite **2a** was performed under the standard conditions by the addition of 3.0 equivalents radical scavengers, such as TEMPO and BHT, and the target product **3a** decreased dramatically. These results indicated that the reaction might proceed *via* a radical pathway.

**Scheme 3** Controlled experiments

Previous works have shown that silver salts can react with *H*-phosphites to form the active $(\text{RO})_2\text{P}(\text{O})\text{Ag}$ complexes which subsequently generate the phosphoryl radical.¹⁶ Based on our controlled experimental results and literature precedents,^{8b, 18} the following plausible mechanism can be proposed for the transformation (**Scheme 4**). The phosphoryl radical **C** may be generated from the complex **B** which itself is formed by the reaction of AgNO_3 catalyst with *H*-phosphites **A**. Subsequently, the radical **C** selectively adds to the β -position of (*E*)- β -nitrostyrene to form a carbon-centered radical **D**, which undergoes an elimination reaction by the leaving NO_2 radical to form the desired product **E**. $\text{Ag}(0)$ could be oxidized back to $\text{Ag}(I)$ by HNO_3 ,^{16a, 18a} thus closing the catalytic cycle.

**Scheme 4** Proposed reaction mechanism for the formation of 2-arylvinyolphosphonates**Conclusions**

In conclusion, we have developed a novel and highly stereoselectivity protocol for the synthesis of 2-

arylvinyolphosphonates starting from (*E*)- β -nitrostyrene through a tandem radical addition-denitration process. This process features a broad substrate scope and functional group tolerance. The reaction proceeded under mild conditions to afford the selective (*E*)-2-arylvinyolphosphonates in moderate to good yields.

Experimental**General information**

Anhydrous solvents were obtained by standard procedure. All substrates purchased from *J & K Scientific Ltd.* were used without further purification. Column chromatography was performed using 300-400 mesh silica with the indicated solvent system according to standard techniques. Nuclear magnetic resonance spectra were recorded on Bruker Avance 400 MHz spectrometer. Chemical shifts for ¹H NMR spectra are recorded in parts per million from tetramethylsilane. Data were reported as follows: chemical shift, multiplicity (*s* = singlet, *d* = doublet, *t* = triplet, *m* = multiplet and *br* = broad), coupling constant in Hz and integration. Chemical shifts for ¹³C NMR spectra were recorded in parts per million from tetramethylsilane. Chemical shift for ³¹P NMR spectra are recorded relative to 85% H_3PO_4 ($\delta = 0$ ppm) as external standard. High resolution mass spectra (HR MS) were obtained on Q-TOF instrument using the ESI technique. IR spectra were recorded on Shimadzu IR-408 Fourier transform infrared spectrophotometer using a thin film supported on KBr pellets. Melting points were measured on an XT4A microscopic apparatus uncorrected.

General procedure for synthesis of 2-arylvinyolphosphonates (3)

(*E*)- β -nitrostyrenes **1** (0.3 mmol), dialkyl *H*-phosphites **2** (0.45 mmol), and AgNO_3 (0.045mmol, 7.6 mg) in CH_3CN (3.0 mL) were added to a 25 mL Schlenk tube. The mixture was heated at 90 °C for 2.0 h (monitored by TLC). After completion of the reaction, the solvent was distilled under vacuum. 10 mL ethylacetate was added to the residuum, 15 mL 5% NaHCO_3 was added to wash two times, and 10 mL saturated NaCl solution washed one time. The organic phase was dried over anhydrous NaSO_4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography to give the desired products **3** using ethyl acetate/petroleum ether (1:3 to 2:1) as eluant.

(E)-Diisopropyl styrylphosphonate (3a)^{8b}

Colorless viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 2978, 2933 ($-\text{CH}_3$), 1614, 1450 (*Ar*-), 1246 ($\text{P}=\text{O}$), 1105 ($\text{P}-\text{O}$). ¹H NMR (CDCl_3) δ : 7.53-7.43 (*m*, 3H), 7.39-7.31 (*m*, 3H), 6.27 (*t*, *J* = 17.6 Hz, 1H), 4.75-4.67 (*m*, 2H), 1.36 (*d*, *J* = 6.2 Hz, 6H), 1.31 (*d*, *J* = 6.2 Hz, 6H). ¹³C NMR (CDCl_3) δ : 147.8 (*d*, *J*_{p-c} = 6.6 Hz), 134.9 (*d*, *J*_{p-c} = 22.9 Hz), 130.0, 128.7, 127.6, 115.5 (*d*, *J*_{p-c} = 190.9 Hz), 70.4 (*d*, *J*_{p-c} = 5.5 Hz), 24.0 (*d*, *J*_{p-c} = 4.1 Hz), 23.9 (*d*, *J*_{p-c} = 4.8 Hz). ³¹P NMR (CDCl_3) δ : 17.4. MS (ESI) *m/z*: 269.3 [*M* + *H*]⁺ (calcd for $\text{C}_{14}\text{H}_{22}\text{O}_3\text{P}^+$ 269.1).

(E)-Diisopropyl 4-methylstyrylphosphonate (3b)^{7b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3126, 2978 (-CH₃), 1616, 1400 (Ar-), 1246 (P=O), 1107 (P-O). ¹H NMR (CDCl₃) δ : 7.46 (dd, $J = 22.6$ Hz, $J = 17.4$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 2H), 7.18 (d, $J = 8.0$ Hz, 2H), 6.20 (t, $J = 17.5$ Hz, 1H), 4.75-4.66 (m, 2H), 2.36 (s, 3H), 1.36 (d, $J = 6.2$ Hz, 6H), 1.31 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 147.8 (d, $J_{\text{P-C}} = 6.7$ Hz), 140.4, 132.3 (d, $J_{\text{P-C}} = 23.3$ Hz), 129.5, 127.6, 114.2 (d, $J_{\text{P-C}} = 191.5$ Hz), 70.4 (d, $J_{\text{P-C}} = 5.6$ Hz), 24.1 (d, $J_{\text{P-C}} = 4.1$ Hz), 24.0 (d, $J_{\text{P-C}} = 4.7$ Hz), 21.4. ³¹P NMR (CDCl₃) δ : 17.8. MS (ESI) m/z : 283.2 [M + H]⁺ (calcd for C₁₅H₂₄O₃P⁺ 283.1).

(E)-Diisopropyl 4-methoxystyrylphosphonate (3c)^{7b}

Colorless viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 2980, 2923 (-CH₃), 1610, 1455 (Ar-), 1244 (P=O), 1103 (P-O). ¹H NMR (CDCl₃) δ : 7.49-7.32 (m, 3H), 6.89 (d, $J = 8.7$ Hz, 2H), 6.10 (t, $J = 17.4$ Hz, 1H), 4.74-4.66 (m, 2H), 3.82 (s, 3H), 1.36 (d, $J = 6.2$ Hz, 6H), 1.31 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 161.1, 147.5 (d, $J_{\text{P-C}} = 6.8$ Hz), 129.2, 127.7 (d, $J_{\text{P-C}} = 23.5$ Hz), 114.1, 112.2 (d, $J_{\text{P-C}} = 192.4$ Hz), 70.3 (d, $J_{\text{P-C}} = 5.4$ Hz), 55.3, 24.0 (d, $J_{\text{P-C}} = 4.0$ Hz), 23.9 (d, $J_{\text{P-C}} = 4.5$ Hz). ³¹P NMR (CDCl₃) δ : 18.3. MS (ESI) m/z : 299.2 [M + H]⁺ (calcd for C₁₅H₂₄O₄P⁺ 299.1).

(E)-Diisopropyl 3,4-dimethoxystyrylphosphonate (3d)¹⁹

Light yellow solid, m.p. 75-76 °C (from chloroform). IR (KBr) $\nu(\text{cm}^{-1})$: 2989, 2954 (-CH₃), 1613, 1458 (Ar-), 1233 (P=O), 1074 (P-O). ¹H NMR (CDCl₃) δ : 7.36 (dd, $J = 22.5$ Hz, $J = 17.4$ Hz, 1H), 7.03 (dd, $J = 8.2$ Hz, $J = 1.8$ Hz, 1H), 6.98 (d, $J = 1.8$ Hz, 1H), 6.81 (d, $J = 8.3$ Hz, 1H), 6.06 (t, $J = 17.4$ Hz, 1H), 4.70-4.62 (m, 2H), 3.86 (s, 6H), 1.32 (d, $J = 6.2$ Hz, 6H), 1.28 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 150.8, 149.1, 147.6 (d, $J_{\text{P-C}} = 6.9$ Hz, CH), 128.0 (d, $J_{\text{P-C}} = 23.5$ Hz), 121.9 (CH), 112.8 (d, $J_{\text{P-C}} = 192.5$ Hz, CH), 110.9 (CH), 109.3 (CH), 70.3 (d, $J_{\text{P-C}} = 5.4$ Hz), 55.9 (CH₃), 55.8 (CH₃), 24.1 (d, $J_{\text{P-C}} = 4.2$ Hz, CH₃), 24.0 (d, $J_{\text{P-C}} = 4.2$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 18.0. MS (ESI) m/z : 329.2 [M + H]⁺ (calcd for C₁₆H₂₆O₅P⁺ 329.1).

(E)-Diisopropyl (2-(benzo[d][1,3]dioxol-5-yl)vinyl)phosphonate (3e)^{6c}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3120, 2978, 2933 (-CH₃, -CH₂), 1601, 1491, 1448 (Ar-), 1254 (P=O), 1105 (P-O). ¹H NMR (CDCl₃) δ : 7.37 (dd, $J = 22.4$ Hz, $J = 17.4$ Hz, 1H), 7.00 (d, $J = 1.1$ Hz, 1H), 6.96 (d, $J = 9.3$ Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.07 (t, $J = 17.2$ Hz, 1H), 5.99 (s, 2H), 4.74-4.65 (m, 2H), 1.36 (d, $J = 6.2$ Hz, 6H), 1.31 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 149.3, 148.2, 147.3 (d, $J_{\text{P-C}} = 7.2$ Hz, CH), 129.4 (d, $J_{\text{P-C}} = 23.8$ Hz), 123.7 (CH), 113.0 (d, $J_{\text{P-C}} = 192.1$ Hz, CH), 107.2 (d, $J_{\text{P-C}} = 225.5$ Hz, CH), 101.4 (CH), 70.3 (d, $J_{\text{P-C}} = 5.5$ Hz), 24.0 (d, $J_{\text{P-C}} = 4.0$ Hz, CH₃), 23.9 (d, $J_{\text{P-C}} = 4.2$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 17.8. MS (ESI) m/z : 313.3 [M + H]⁺ (calcd for C₁₅H₂₂O₅P⁺ 313.1).

(E)-Diisopropyl 2-chlorostyrylphosphonate (3f)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3128, 2979 (-CH₃), 1614, 1450, 1367 (Ar-), 1248 (P=O), 1105 (P-O), 754 (C-Cl). ¹H NMR (CDCl₃) δ : 7.83 (dd, $J = 22.6$ Hz, $J = 17.5$ Hz, 1H), 7.60-7.57 (m, 1H), 7.40-7.38

(m, 1H), 7.31-7.27 (m, 2H), 6.31 (t, $J = 17.6$ Hz, 1H), 4.79-4.70 (m, 2H), 1.36 (dd, $J = 12.7$ Hz, $J = 6.2$ Hz, 12H). ¹³C NMR (CDCl₃) δ : 143.0 (d, $J_{\text{P-C}} = 7.8$ Hz), 134.4, 133.2 (d, $J_{\text{P-C}} = 23.7$ Hz), 130.8, 130.0 (d, $J_{\text{P-C}} = 1.0$ Hz), 127.3, 127.0, 119.8, 117.9, 70.7 (d, $J_{\text{P-C}} = 5.7$ Hz), 24.1 (d, $J_{\text{P-C}} = 4.0$ Hz), 24.0 (d, $J_{\text{P-C}} = 4.8$ Hz). ³¹P NMR (CDCl₃) δ : 16.0. HR MS (ESI) m/z : 303.0914 [M + H]⁺ (calcd for C₁₄H₂₁ClO₃P⁺ 303.0911).

(E)-Diisopropyl 2,6-dichlorostyrylphosphonate (3g)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3120, 3020 (-CH₃), 1610, 1589 (Ar-), 1252 (P=O), 1153 (P-O), 756 (C-Cl). ¹H NMR (CDCl₃) δ : 7.51 (dd, $J = 23.6$ Hz, $J = 17.8$ Hz, 1H), 7.34 (d, $J = 8.0$ Hz, 2H), 7.18 (t, $J = 8.0$ Hz, 1H), 6.43 (t, $J = 18.0$ Hz, 1H), 4.80-4.72 (m, 2H), 1.38 (d, $J = 6.2$ Hz, 6H), 1.31 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 141.3 (d, $J_{\text{P-C}} = 7.8$ Hz), 134.5 (d, $J_{\text{P-C}} = 1.5$ Hz), 132.8 (d, $J_{\text{P-C}} = 23.4$ Hz), 129.6, 128.7, 125.8 (d, $J_{\text{P-C}} = 183.2$ Hz), 70.5 (d, $J_{\text{P-C}} = 5.4$ Hz), 24.1 (d, $J_{\text{P-C}} = 4.0$ Hz), 23.9 (d, $J_{\text{P-C}} = 4.5$ Hz). ³¹P NMR (CDCl₃) δ : 14.6. HR MS (ESI) m/z : 337.0518 [M + H]⁺ (calcd for C₁₄H₂₀Cl₂O₃P⁺ 337.0522).

(E)-diisopropyl 4-fluorostyrylphosphonate (3h)^{7b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3082, 2930 (-CH₃), 1614, 1457 (Ar-), 1248 (P=O), 1108 (P-O). ¹H NMR (CDCl₃) δ : 7.45-7.34 (m, 3H), 7.02 (d, $J = 8.6$ Hz, 2H), 6.14 (t, $J = 17.2$ Hz, 1H), 4.71-4.63 (m, 2H), 1.32 (d, $J = 6.2$ Hz, 6H), 1.28 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 163.7 (d, $J_{\text{F-C}} = 249.1$ Hz), 146.4 (d, $J_{\text{P-C}} = 6.9$ Hz, CH), 131.2 (dd, $J_{\text{F-C}} = 3.4$ Hz, $J_{\text{P-C}} = 23.5$ Hz), 129.4 (d, $J_{\text{P-C}} = 8.4$ Hz, CH), 115.8 (d, $J_{\text{P-C}} = 21.8$ Hz, CH), 115.3 (dd, $J_{\text{F-C}} = 2.0$ Hz, $J_{\text{P-C}} = 191.7$ Hz, CH), 70.5 (d, $J_{\text{P-C}} = 5.5$ Hz, CH), 24.0 (d, $J_{\text{P-C}} = 4.0$ Hz, CH₃), 23.9 (d, $J_{\text{P-C}} = 4.0$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 17.0. ¹⁹F NMR (CDCl₃) δ : -110.2. MS (ESI) m/z : 287.3 [M + H]⁺ (calcd for C₁₄H₂₁FO₃P⁺ 287.1).

(E)-diisopropyl 4-bromostyrylphosphonate (3i)^{8b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3325, 2960 (-CH₃), 1616 (Ar-), 1250 (P=O), 1116 (P-O). ¹H NMR (CDCl₃) δ : 7.51-7.39 (m, 3H), 7.34 (d, $J = 8.4$ Hz, 2H), 6.24 (t, $J = 17.2$ Hz, 1H), 4.76-4.66 (m, 2H), 1.35 (d, $J = 6.2$ Hz, 6H), 1.30 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 146.4 (d, $J_{\text{P-C}} = 7.0$ Hz), 133.9 (d, $J_{\text{P-C}} = 23.5$ Hz), 132.0, 129.0, 124.2, 116.2 (d, $J_{\text{P-C}} = 191.5$ Hz), 70.5 (d, $J_{\text{P-C}} = 5.8$ Hz), 24.0 (d, $J_{\text{P-C}} = 4.0$ Hz), 23.9 (d, $J_{\text{P-C}} = 4.5$ Hz). ³¹P NMR (CDCl₃) δ : 16.6. MS (ESI) m/z : 347.2 [M + H]⁺ (calcd for C₁₄H₂₁BrO₃P⁺ 347.0).

(E)-diisopropyl 4-iodostyrylphosphonate (3j)

Yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3028, 2965 (-CH₃), 1624, 1547 (Ar-), 1246 (P=O), 1109 (P-O). ¹H NMR (CDCl₃) δ : 7.70 (d, $J = 8.4$ Hz, 2H), 7.37 (dd, $J = 17.6$ Hz, $J = 22.6$ Hz, 1H), 7.20 (d, $J = 8.4$ Hz, 2H), 6.25 (t, $J = 17.2$ Hz, 1H), 4.73-4.65 (m, 2H), 1.35 (d, $J = 6.2$ Hz, 6H), 1.30 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 146.4 (d, $J_{\text{P-C}} = 6.7$ Hz), 138.0, 134.5 (d, $J_{\text{P-C}} = 23.3$ Hz), 129.1, 127.6, 116.6 (d, $J_{\text{P-C}} = 191.0$ Hz), 70.6 (d, $J_{\text{P-C}} = 5.7$ Hz), 24.1 (d, $J_{\text{P-C}} = 4.0$ Hz), 24.0 (d, $J_{\text{P-C}} = 4.5$ Hz). ³¹P NMR (CDCl₃) δ : 16.6. HR MS (ESI) m/z : 395.0270 [M + H]⁺ (calcd for C₁₄H₂₁IO₃P⁺ 395.0268).

(E)-diisopropyl (2-(thiophen-2-yl)vinyl)phosphonate (3k)^{7b}

Colorless viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3007, 2926 (-CH₃), 1613, 1452 (Ar-), 1245 (P=O), 1103 (P-O). ¹H NMR (CDCl₃) δ : 7.49 (dd, $J = 22.6$ Hz, $J = 17.4$ Hz, 1H), 7.28 (d, $J = 5.0$ Hz, 1H), 7.13 (d, $J = 3.3$ Hz, 1H), 6.97 (t, $J = 4.6$ Hz, 1H), 5.95 (t, $J = 16.8$ Hz, 1H), 4.69-4.59 (m, 2H), 1.30 (d, $J = 6.2$ Hz, 6H), 1.26 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 140.5 (d, $J_{\text{P-C}} = 26.7$ Hz), 140.2 (d, $J_{\text{P-C}} = 7.6$ Hz, CH), 129.9 (CH), 127.9 (d, $J_{\text{P-C}} = 1.1$ Hz, CH), 127.8, 114.1 (d, $J_{\text{P-C}} = 193.1$ Hz, CH), 70.5 (d, $J_{\text{P-C}} = 5.5$ Hz, CH), 24.0 (d, $J_{\text{P-C}} = 4.0$ Hz, CH₃), 23.9 (d, $J_{\text{P-C}} = 4.0$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 16.7. MS (ESI) m/z : 275.2 [M + H]⁺ (calcd for C₁₂H₂₀O₃P⁺ 275.0).

(E)-diisopropyl (1-phenylprop-1-en-2-yl)phosphonate (3l)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3125, 3018 (-CH₃), 1612, 1576 (Ar-), 1250 (P=O), 1132 (P-O). ¹H NMR (CDCl₃) δ : 7.47 (dd, $J = 24.8$ Hz, $J = 1.4$ Hz, 1H), 7.38 (d, $J = 4.4$ Hz, 4H), 7.34-7.29 (m, 1H), 4.71-4.68 (m, 2H), 2.06 (dd, $J = 15.2$ Hz, $J = 1.4$ Hz, 1H), 1.38 (d, $J = 6.2$ Hz, 6H), 1.31 (d, $J = 6.2$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 141.9 (d, $J_{\text{P-C}} = 12.5$ Hz, CH), 135.9 (d, $J_{\text{P-C}} = 23.4$ Hz), 129.4 (CH), 128.4 (CH), 128.2 (CH), 126.4, 70.3 (d, $J_{\text{P-C}} = 6.4$ Hz, CH), 24.1 (d, $J_{\text{P-C}} = 4.2$ Hz, CH₃), 23.8 (d, $J_{\text{P-C}} = 4.5$ Hz, CH₃), 14.4 (d, $J_{\text{P-C}} = 9.7$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 19.7. HR MS (ESI) m/z : 283.1456 [M + H]⁺ (calcd for C₁₅H₂₄O₃P⁺ 283.1458).

(E)-Dimethyl styrylphosphonate (3m)²⁰

Colorless viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 2952, 2850 (-CH₃), 1616, 1448 (Ar-), 1250 (P=O), 1053 (P-O). ¹H NMR (CDCl₃) δ : 7.58-7.48 (m, 3H), 7.40-7.37 (m, 3H), 6.23 (t, $J = 17.7$ Hz, 1H), 3.78 (d, $J = 11.1$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 149.6 (d, $J_{\text{P-C}} = 6.6$ Hz), 134.6 (d, $J_{\text{P-C}} = 23.1$ Hz), 130.4, 128.9, 127.7, 112.3 (d, $J_{\text{P-C}} = 191.2$ Hz), 52.4 (d, $J_{\text{P-C}} = 5.6$ Hz). ³¹P NMR (CDCl₃) δ : 22.4. MS (ESI) m/z : 213.1 [M + H]⁺ (calcd for C₁₀H₁₄O₃P⁺ 213.0).

(E)-Diethyl styrylphosphonate (3n)^{8b}

Colorless viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3107, 1985 (-CH₃, -CH₂), 1610, 1545, 1464 (Ar-), 1214 (P=O), 1134 (P-O). ¹H NMR (CDCl₃) δ : 7.56-7.46 (m, 3H), 7.40-7.37 (m, 3H), 6.26 (t, $J = 17.6$ Hz, 1H), 4.17-4.09 (m, 4H), 1.36 (t, $J = 7.0$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 148.7 (d, $J_{\text{P-C}} = 6.7$ Hz), 134.8 (d, $J_{\text{P-C}} = 23.0$ Hz), 130.2, 128.8, 127.7, 113.9 (d, $J_{\text{P-C}} = 190.3$ Hz), 61.8 (d, $J_{\text{P-C}} = 5.5$ Hz), 16.4 (d, $J_{\text{P-C}} = 6.4$ Hz). ³¹P NMR (CDCl₃) δ : 19.5. MS (ESI) m/z : 241.3 [M + H]⁺ (calcd for C₁₂H₁₈O₃P⁺ 241.1).

(E)-Dipropyl styrylphosphonate (3o)^{7a}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3122, 2970 (-CH₃, -CH₂), 1616, 1400 (Ar-), 1244 (P=O), 1065 (P-O). ¹H NMR (CDCl₃) δ : 7.56-7.46 (m, 3H), 7.39-7.37 (m, 3H), 6.26 (t, $J = 17.6$ Hz, 1H), 4.05-3.99 (m, 4H), 1.76-1.68 (m, 4H), 0.97 (d, $J = 7.4$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 148.8 (d, $J_{\text{P-C}} = 6.7$ Hz), 134.8 (d, $J_{\text{P-C}} = 23.2$ Hz), 130.3, 128.9, 127.7, 113.6 (d, $J_{\text{P-C}} = 191.0$ Hz), 67.4 (d, $J_{\text{P-C}} = 5.8$ Hz), 23.8 (d, $J_{\text{P-C}} = 6.5$ Hz), 10.0. ³¹P NMR (CDCl₃) δ : 19.6. MS (ESI) m/z : 269.2 [M + H]⁺ (calcd for C₁₄H₂₂O₃P⁺ 269.1).

(E)-dibutyl styrylphosphonate (3p)^{7b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3128, 2962 (-CH₃, -CH₂), 1526, 1415 (Ar-), 1248 (P=O), 1068 (P-O). ¹H NMR (CDCl₃) δ : 7.52-7.42 (m, 3H), 7.36-7.33 (m, 3H), 6.24 (t, $J = 17.6$ Hz, 1H), 4.06-3.98 (m, 4H), 1.67-1.60 (m, 4H), 1.43-1.35 (m, 4H), 0.89 (t, $J = 7.4$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 148.7 (d, $J_{\text{P-C}} = 6.6$ Hz, CH), 134.8 (d, $J_{\text{P-C}} = 23.1$ Hz), 130.2 (CH), 128.8 (CH), 127.7 (CH), 113.8 (d, $J_{\text{P-C}} = 190.4$ Hz, CH), 65.5 (d, $J_{\text{P-C}} = 5.7$ Hz, CH₂), 32.5 (d, $J_{\text{P-C}} = 6.3$ Hz, CH₂), 18.7 (CH₂), 13.6 (CH₃). ³¹P NMR (CDCl₃) δ : 19.6. MS (ESI) m/z : 297.3 [M + H]⁺ (calcd for C₁₆H₂₆O₃P⁺ 297.1).

(E)-Diisobutyl styrylphosphonate (3q)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3124, 2969 (-CH₃, -CH₂), 1608, 1410 (Ar-), 1167 (P=O), 1047 (P-O). ¹H NMR (CDCl₃) δ : 7.57-7.47 (m, 3H), 7.39-7.37 (m, 3H), 6.26 (t, $J = 17.6$ Hz, 1H), 3.85-3.80 (m, 4H), 2.00-1.93 (m, 2H), 0.95 (d, $J = 6.8$ Hz, 9H). ¹³C NMR (CDCl₃) δ : 148.9 (d, $J_{\text{P-C}} = 6.5$ Hz), 134.8 (d, $J_{\text{P-C}} = 23.3$ Hz), 130.3, 128.9, 127.7, 113.4 (d, $J_{\text{P-C}} = 191.7$ Hz), 71.9 (d, $J_{\text{P-C}} = 6.1$ Hz), 29.1 (d, $J_{\text{P-C}} = 6.7$ Hz), 18.7 (d, $J_{\text{P-C}} = 1.9$ Hz). ³¹P NMR (CDCl₃) δ : 19.4. HR MS (ESI) m/z : 297.1618 [M + H]⁺ (calcd for C₁₆H₂₆O₃P⁺ 297.1614).

(E)-diphenyl(styryl)phosphine oxide (3r)^{8b}

Light yellow solid, m.p. 145-146 °C (from chloroform). IR (KBr) $\nu(\text{cm}^{-1})$: 1606, 1437, 1400 (Ar-), 1162 (P=O), 1120 (P-O). ¹H NMR (CDCl₃) δ : 7.77-7.72 (m, 4H), 7.55-7.44 (m, 9H), 7.36-7.35 (m, 3H), 6.83 (dd, $J = 22.4$ Hz, $J = 17.4$ Hz, 1H). ¹³C NMR (CDCl₃) δ : 147.6 (d, $J_{\text{P-C}} = 3.5$ Hz, CH), 135.1 (d, $J_{\text{P-C}} = 17.8$ Hz), 132.8 (d, $J_{\text{P-C}} = 105.5$ Hz), 131.9 (d, $J_{\text{P-C}} = 2.5$ Hz, CH), 131.4 (d, $J_{\text{P-C}} = 10.0$ Hz, CH), 130.1, 128.8 (d, $J_{\text{P-C}} = 27.8$ Hz, CH), 128.7 (CH), 127.8 (CH), 119.0 (d, $J_{\text{P-C}} = 103.9$ Hz, CH). ³¹P NMR (CDCl₃) δ : 24.8. MS (ESI) m/z : 305.0 [M + H]⁺ (calcd for C₂₀H₁₈OP⁺ 305.1).

(E)-Diethyl 4-methylstyrylphosphonate (3s)^{8b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3128, 2969 (-CH₃, -CH₂), 1616, 1405 (Ar-), 1246 (P=O), 1026 (P-O). ¹H NMR (CDCl₃) δ : 7.47 (dd, $J = 22.6$ Hz, $J = 17.5$ Hz, 1H), 7.39 (d, $J = 8.1$ Hz, 2H), 7.18 (d, $J = 8.1$ Hz, 2H), 6.19 (t, $J = 17.7$ Hz, 1H), 4.16-4.08 (m, 4H), 2.37 (s, 3H), 1.35 (t, $J = 7.0$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 148.8 (d, $J_{\text{P-C}} = 6.6$ Hz), 140.6, 132.1 (d, $J_{\text{P-C}} = 23.2$ Hz), 129.5, 127.7, 112.4 (d, $J_{\text{P-C}} = 190.8$ Hz), 61.8 (d, $J_{\text{P-C}} = 5.4$ Hz), 21.4, 16.4 (d, $J_{\text{P-C}} = 6.5$ Hz). ³¹P NMR (CDCl₃) δ : 19.9. MS (ESI) m/z : 255.0 [M + H]⁺ (calcd for C₁₃H₂₀O₃P⁺ 255.1).

(E)-Diethyl 4-methoxystyrylphosphonate (3t)^{8b}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3134, 2969 (-CH₃, -CH₂), 1604, 1512, 1400 (Ar-), 1257 (P=O), 1028 (P-O). ¹H NMR (CDCl₃) δ : 7.46-7.36 (m, 3H), 6.86 (d, $J = 8.8$ Hz, 2H), 6.05 (t, $J = 17.6$ Hz, 1H), 4.12-4.04 (m, 4H), 3.79 (s, 3H), 1.31 (t, $J = 7.1$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 161.2, 148.4 (d, $J_{\text{P-C}} = 6.9$ Hz, CH), 129.3 (CH), 127.6 (d, $J_{\text{P-C}} = 23.7$ Hz), 114.2 (CH), 110.6 (d, $J_{\text{P-C}} = 191.7$ Hz, CH), 61.7 (d, $J_{\text{P-C}} = 5.3$ Hz, CH₂), 55.3 (CH₃), 16.4 (d, $J_{\text{P-C}} = 6.5$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 20.4. MS (ESI) m/z : 271.3 [M + H]⁺ (calcd for C₁₃H₂₀O₄P⁺ 271.1).

(E)-Diethyl 2-chlorostyrylphosphonate (3u)^{8a}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3132, 2969 (-CH₃, -CH₂), 1595, 1401 (Ar-), 1254 (P=O), 1075 (P-O), 806 (C-Cl). ¹H NMR (CDCl₃) δ : 7.86 (dd, $J = 22.6$ Hz, $J = 17.5$ Hz, 1H), 7.61-7.58 (m, 1H), 7.41-7.39 (m, 1H), 7.31-7.28 (m, 2H), 6.30 (t, $J = 17.7$ Hz, 1H), 4.20-4.12 (m, 4H), 1.37 (t, $J = 7.0$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 144.0 (d, $J_{\text{p-c}} = 7.8$ Hz), 134.5, 133.2 (d, $J_{\text{p-c}} = 23.5$ Hz), 131.0, 130.0, 127.4, 127.0, 117.2 (d, $J_{\text{p-c}} = 33.0$ Hz), 62.1 (d, $J_{\text{p-c}} = 5.6$ Hz), 16.4 (d, $J_{\text{p-c}} = 6.4$ Hz). ³¹P NMR (CDCl₃) δ : 18.2. MS (ESI) m/z : 275.2 [M + H]⁺ (calcd for C₁₂H₁₇ClO₃P⁺ 275.0).

(E)-Diethyl 2,6-dichlorostyrylphosphonate (3v)^{8a}

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3125, 3018 (-CH₃, -CH₂), 1615, 1578 (Ar-), 1250 (P=O), 1151 (P-O), 764 (C-Cl). ¹H NMR (CDCl₃) δ : 7.53 (dd, $J = 23.7$ Hz, $J = 17.9$ Hz, 1H), 7.36 (d, $J = 7.7$ Hz, 2H), 7.19 (t, $J = 8.2$ Hz, 1H), 6.42 (t, $J = 18.2$ Hz, 1H), 4.21-4.14 (m, 4H), 1.38 (d, $J = 7.0$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 142.1 (d, $J_{\text{p-c}} = 7.6$ Hz), 134.5 (d, $J_{\text{p-c}} = 1.4$ Hz), 129.8, 128.7, 127.9, 124.2 (d, $J_{\text{p-c}} = 182.5$ Hz), 62.2 (d, $J_{\text{p-c}} = 5.4$ Hz), 16.4 (d, $J_{\text{p-c}} = 6.4$ Hz). ³¹P NMR (CDCl₃) δ : 17.0. MS (ESI) m/z : 309.2 [M + H]⁺ (calcd for C₁₂H₁₆Cl₂O₃P⁺ 309.0).

(E)-diethyl (2-(benzo[d][1,3]dioxol-5-yl)vinyl)phosphonate (3w)²¹

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3138, 2969 (-CH₃, -CH₂), 1603, 1590, 1401 (Ar-), 1254 (P=O), 1038 (P-O). ¹H NMR (CDCl₃) δ : 7.33 (dd, $J = 22.4$ Hz, $J = 17.4$ Hz, 1H), 6.94 (s, 1H), 6.90 (d, $J = 8.0$ Hz, 1H), 6.73 (d, $J = 8.0$ Hz, 1H), 5.98 (t, $J = 17.4$ Hz, 1H), 5.93 (s, 2H), 4.09-4.01 (m, 4H), 1.28 (t, $J = 7.1$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 149.4, 148.4, 148.3 (d, $J_{\text{p-c}} = 3.8$ Hz, CH), 129.3 (d, $J_{\text{p-c}} = 23.8$ Hz), 123.9 (CH), 112.3 (CH), 110.4 (CH), 108.4 (CH), 106.2 (CH), 101.5 (CH₂), 61.7 (d, $J_{\text{p-c}} = 5.5$ Hz, CH₂), 16.3 (d, $J_{\text{p-c}} = 6.4$ Hz, CH₃). ³¹P NMR (CDCl₃) δ : 19.6. MS (ESI) m/z : 285.2 [M + H]⁺ (calcd for C₁₃H₁₈O₅P⁺ 285.0).

Tetraethyl (2-(benzo[d][1,3]dioxol-5-yl)ethene-1,1-diyl)bis(phosphonate) (3w')

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3122, 2987 (-CH₃, -CH₂), 1603, 1405 (Ar-), 1254 (P=O), 1106 (P-O). ¹H NMR (CDCl₃) δ : 8.18 (dd, $J = 29.4$ Hz, $J = 47.7$ Hz, 1H), 7.55 (d, $J = 1.3$ Hz, 1H), 7.30 (d, $J = 8.2$ Hz, 1H), 6.83 (d, $J = 8.2$ Hz, 1H), 6.83 (s, 2H), 4.22-4.14 (m, 4H), 4.13-4.05 (m, 4H), 1.37 (t, $J = 7.0$ Hz, 6H), 1.24 (t, $J = 7.0$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 161.1 (d, $J_{\text{p-c}} = 2.2$ Hz), 150.1, 147.6, 128.3 (dd, $J_{\text{p-c}} = 22.6$ Hz, $J_{\text{p-c}} = 8.8$ Hz), 127.8, 110.6, 107.9, 101.6, 62.6 (d, $J_{\text{p-c}} = 5.2$ Hz), 62.4 (d, $J_{\text{p-c}} = 5.8$ Hz), 16.3 (d, $J_{\text{p-c}} = 6.6$ Hz), 16.1 (d, $J_{\text{p-c}} = 6.6$ Hz). ³¹P NMR (CDCl₃) δ : 18.3 (d, $J_{\text{p-p}} = 49.5$ Hz), 12.8 (d, $J_{\text{p-p}} = 49.5$ Hz). HR MS (ESI) m/z : 421.1178 [M + H]⁺ (calcd for C₁₇H₂₇O₈P₂⁺ 421.1176).

(E)-Dipropyl (2-(benzo[d][1,3]dioxol-5-yl)vinyl)phosphonate (3x)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3140, 2967 (-CH₃, -CH₂), 1607, 1582, 1406 (Ar-), 1247 (P=O), 1036 (P-O). ¹H NMR (CDCl₃) δ : 7.40 (dd, $J = 22.4$ Hz, $J = 17.4$ Hz, 1H), 7.01 (d, $J = 1.3$ Hz, 1H), 6.97 (d, $J = 8.0$ Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 1H), 6.09-6.00 (m, 3H), 4.03-3.97 (m, 4H), 1.76-1.67 (m, 4H), 0.96 (t, $J = 7.4$ Hz, 6H). ¹³C NMR

(CDCl₃) δ : 149.4, 148.3 (d, $J_{\text{p-c}} = 5.0$ Hz), 129.3 (d, $J_{\text{p-c}} = 23.7$ Hz), 123.9, 112.3, 110.4, 108.4, 106.2, 101.5, 67.3 (d, $J_{\text{p-c}} = 5.5$ Hz), 23.8 (d, $J_{\text{p-c}} = 6.5$ Hz), 10.1. ³¹P NMR (CDCl₃) δ : 20.1. HR MS (ESI) m/z : 313.1202 [M + H]⁺ (calcd for C₁₅H₂₂O₅P⁺ 313.1199).

(E)-Dibenzyl (2-(benzo[d][1,3]dioxol-5-yl)vinyl)phosphonate (3y)

Light yellow solid, m.p. 106-107 °C (from chloroform). IR (KBr) $\nu(\text{cm}^{-1})$: 3126, 3033 (-CH₂), 1601, 1491, 1448, 1400 (Ar-), 1254 (P=O), 1036 (P-O). ¹H NMR (CDCl₃) δ : 7.38-7.29 (m, 11H), 6.90-6.87 (m, 2H), 6.76 (d, $J = 7.9$ Hz, 1H), 6.01 (t, $J = 17.6$ Hz, 1H), 5.96 (s, 2H), 5.07 (s, 2H), 5.05 (s, 2H). ¹³C NMR (CDCl₃) δ : 149.6, 148.7 (d, $J_{\text{p-c}} = 7.2$ Hz, CH), 136.3 (d, $J_{\text{p-c}} = 6.6$ Hz), 129.2 (d, $J_{\text{p-c}} = 24.4$ Hz), 128.6 (CH), 128.4 (CH), 127.9 (CH), 124.0 (CH), 111.0 (d, $J_{\text{p-c}} = 192.8$ Hz, CH), 108.4 (CH), 106.2 (CH), 101.5 (CH₂), 67.4 (d, $J_{\text{p-c}} = 5.2$ Hz, CH₂). ³¹P NMR (CDCl₃) δ : 21.1. HR MS (ESI) m/z : 409.1196 [M + H]⁺ (calcd for C₂₃H₂₂O₅P⁺ 409.1199).

(E)-Dibenzyl 2-chlorostyrylphosphonate (3z)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3126 (-CH₂), 1603, 1401 (Ar-), 1250 (P=O), 1049 (P-O). ¹H NMR (CDCl₃) δ : 7.87 (dd, $J = 23.0$ Hz, $J = 17.5$ Hz, 1H), 7.47 (dd, $J = 7.5$ Hz, $J = 1.6$ Hz, 1H), 7.39-7.24 (m, 13H), 6.24 (t, $J = 18.1$ Hz, 1H), 5.11 (d, $J = 2.8$ Hz, 2H), 5.09 (d, $J = 2.7$ Hz, 2H). ¹³C NMR (CDCl₃) δ : 144.4 (d, $J_{\text{p-c}} = 8.1$ Hz, CH), 136.1 (d, $J_{\text{p-c}} = 6.5$ Hz), 134.6, 133.0 (d, $J_{\text{p-c}} = 23.9$ Hz), 131.0 (CH), 130.1 (CH), 128.6 (CH), 128.4 (CH), 128.0 (CH), 127.4 (d, $J_{\text{p-c}} = 1.0$ Hz, CH), 127.0 (CH), 116.9 (d, $J_{\text{p-c}} = 190.9$ Hz, CH), 67.5 (d, $J_{\text{p-c}} = 5.6$ Hz, CH₂). ³¹P NMR (CDCl₃) δ : 19.2. HR MS (ESI) m/z : 399.0909 [M + H]⁺ (calcd for C₂₂H₂₁ClO₃P⁺ 399.0911).

(E)-dibutyl 3,4-dimethoxystyrylphosphonate (3zz)

Light yellow viscous liquid. IR (KBr) $\nu(\text{cm}^{-1})$: 3147, 2962 (-CH₃, -CH₂), 1514, 1400 (Ar-), 1269 (P=O), 1159 (P-O). ¹H NMR (CDCl₃) δ : 7.37 (dd, $J = 22.4$ Hz, $J = 17.4$ Hz, 1H), 7.02 (dd, $J = 8.2$ Hz, $J = 1.5$ Hz, 1H), 6.98 (d, $J = 1.5$ Hz, 1H), 6.81 (d, $J = 8.3$ Hz, 1H), 6.04 (t, $J = 17.4$ Hz, 1H), 4.03-3.96 (m, 4H), 3.85 (s, 6H), 1.66-1.59 (m, 4H), 1.41-1.32 (m, 4H), 0.87 (t, $J = 7.4$ Hz, 6H). ¹³C NMR (CDCl₃) δ : 150.9, 149.1, 148.5 (d, $J_{\text{p-c}} = 6.9$ Hz, CH), 127.8 (d, $J_{\text{p-c}} = 23.5$ Hz), 122.0 (CH), 111.0 (d, $J_{\text{p-c}} = 191.9$ Hz, CH), 110.9 (CH), 109.3 (CH), 65.5 (CH₃), 65.4 (CH₃), 55.9 (d, $J_{\text{p-c}} = 8.9$ Hz, CH₂), 32.5 (d, $J_{\text{p-c}} = 6.5$ Hz, CH₂), 18.7 (CH₂), 13.6 (CH₃). ³¹P NMR (CDCl₃) δ : 19.8. HR MS (ESI) m/z : 357.1823 [M + H]⁺ (calcd for C₁₈H₃₀O₅P⁺ 357.1825).

Acknowledgements

We gratefully acknowledge the National Natural Science Foundation of China (No. 21302042 and 21172055), Department of Henan Province Natural Science and Technology Foundation (No. 142102210410), Natural Science Foundation in Henan Province Department of Education (No. 14B150053 and 17A150005), the Program for Innovative Research Team from Zhengzhou (No. 131PCXTD605).

Notes and references

ARTICLE

Journal Name


- 1 (a) M. Maffei, *Curr. Org. Chem.*, **2004**, *1*, 355; (b) L. Coudray, J. L. Montchamp, *Eur. J. Org. Chem.*, **2008**, 3601.
- 2 (a) Z. C. Duan, X. P. Hu, D. Y. Wang, J. D. Huang, S. B. Yu, J. Deng, Z. Zheng, *Adv. Synth. Catal.*, **2008**, *10*, 3141; (b) C. Garzon, M. Attolini, M. Maffei, *Eur. J. Org. Chem.*, **2013**, 3653; (c) J. Ito, K. Fujii, H. Nishiyama, *Chem. Eur. J.*, **2013**, *19*, 601; (d) D. Ender, H. Wahl, K. Papadopoulos, *Tetrahedron*, **1997**, *53*, 13961; (e) H. Inoue, H. Tsubouchi, Y. Nagaoka, K. Tomioka, *Tetrahedron*, **2002**, *58*, 83.
- 3 (a) S. Salzinger, B. S. Soller, A. Plikhta, U. B. Seemann, E. Herdtweck, B. Rieger, *J. Am. Chem. Soc.*, **2013**, *135*, 13030; (b) S. Jin, K. E. Gonsalves, *Macromolecules*, **1998**, *31*, 1010; (c) J. A. Russell, F. A. Ching, H. I. Tashtoush, J. E. Russell, D. F. Dedolph, *J. Org. Chem.*, **1991**, *56*, 663; (d) M. Ruiz, M. C. Fernández, S. Conde, A. Diaz, J. M. Quintela, *Synlett*, **1999**, 1903.
- 4 (a) A. Quntar, O. Baum, R. Reich, M. Srebnik, *Arch. Pharm. Pharm. Med. Chem.*, **2004**, *337*, 76; (b) Z. Liu, N. MacRitchie, S. Pyne, N. J. Pyne, R. Bittman, *Bioorg. Med. Chem.*, **2013**, *21*, 2503; (c) T. Minami, J. Motoyoshiya, *Synthesis*, **1992**, 333; (d) M. R. Harnden, A. Parkin, M. J. Parratt, R. M. Perkins, *J. Med. Chem.*, **1993**, *36*, 1343.
- 5 (a) X. Mi, M. M. Huang, J. Y. Zhang, C. Y. Wang, Y. J. Wu, *Org. Lett.*, **2013**, *15*, 6266; (b) Y. M. Li, Y. Shen, K. J. Chang, S. D. Yang, *Tetrahedron Lett.*, **2014**, *55*, 2119; (c) J. W. Yuan, Y. Z. Li, L. R. Yang, W. P. Mai, P. Mao, Y. M. Xiao, L. B. Qu, *Tetrahedron*, **2015**, *71*, 8178.
- 6 (a) G. Evano, K. Tadiparthi, F. Couty, *Chem. Commun.*, **2011**, 47, 179; (b) L. L. Mao, A. X. Zhou, N. Liu, S. D. Yang, *Synlett*, **2014**, 25, 2727; (c) J. Hu, N. Zhao, B. Yang, G. Wang, L. N. Guo, Y. M. Liang, S. D. Yang, *Chem. Eur. J.*, **2011**, *17*, 5516; (d) S. Thielges, P. Bissereet, J. Eustache, *Org. Lett.*, **2005**, *7*, 681.
- 7 (a) L. Liu, Y. Lv, Y. L. Wu, X. Gao, Z. P. Zeng, Y. X. Gao, G. Tang, Y. F. Zhao, *RSC Adv.*, **2014**, *4*, 2322; (b) Y. L. Wu, L. Liu, K. L. Yan, P. X. Xu, Y. X. Gao, Y. F. Zhao, *J. Org. Chem.*, **2014**, *79*, 8118.
- 8 (a) J. F. Xue, S. F. Zhou, Y. Y. Liu, X. Q. Pan, J. P. Zou, O. T. Asekun, *Org. Biomol. Chem.*, **2015**, *13*, 4896; (b) Q. W. Gui, L. Hu, X. Chen, J. D. Liu, Z. Tan, *Chem. Commun.*, **2015**, *51*, 13922.
- 9 (a) P. Zhong, X. Huang, Z. X. Xiong, *Synlett*, **1999**, 6, 721; (b) P. Zhong, Z. X. Xiong, X. Huang, *Synthetic Commun.*, **2000**, *30*, 273; (c) L. B. Han, M. Tanaka, *J. Am. Chem. Soc.*, **1996**, *118*, 1571; (d) L. B. Han, C. Q. Zhao, M. Tanaka, *J. Org. Chem.*, **2001**, *66*, 5929.
- 10 (a) G. W. Kabalka, S. K. Guchhait, *Org. Lett.*, **2003**, *5*, 729; (b) G. Axelrad, S. Laosooksathit, R. Engel, *Synthetic Commun.*, **1980**, *10*, 933.
- 11 (a) G. W. Kabalka, S. K. Guchhait, A. Naravane, *Tetrahedron Lett.*, **2004**, *45*, 4685; (b) M. M. D. Pramanik, A. K. Chaturvedi, N. Rastogi, *Chem. Commun.*, **2014**, *50*, 12896.
- 12 (a) E. J. Corey, H. Estreicher, *J. Am. Chem. Soc.*, **1978**, *100*, 6294; (b) A. G. M. Barrett, G. G. Graboski, *Chem. Rev.*, **1986**, *86*, 751; (c) J. T. Liu, Y. J. Jang, Y. K. Shih, S. R. Hu, C. M. Chu, C. F. Yao, *J. Org. Chem.*, **2001**, *66*, 6021.
- 13 (a) J. C. Anderson, A. S. Kalogirou, G. J. Tizzard, *Tetrahedron*, **2014**, *70*, 9337; (b) C. F. Yao, C. M. Chu, J. T. Liu, *J. Org. Chem.*, **1998**, *63*, 719; (c) J. Y. Liu, J. T. Liu, C. F. Yao, *Tetrahedron Lett.*, **2001**, *42*, 3613.
- 14 Y. J. Jang, M. C. Yan, Y. F. Lin, C. F. Yao, *J. Org. Chem.*, **2004**, *69*, 3961.
- 15 (a) W. P. Mai, G. C. Sun, J. T. Wang, G. Song, P. Mao, L. R. Yang, J. W. Yuan, Y. M. Xiao, L. B. Qu, *J. Org. Chem.*, **2014**, *79*, 8094; (b) W. P. Mai, J. T. Wang, L. R. Yang, J. W. Yuan, Y. M. Xiao, P. Mao, L. B. Qu, *Org. Lett.*, **2014**, *16*, 204; (c) W. M. Zhao, X. L. Chen, J. W. Yuan, L. B. Qu, L. K. Duan, Y. F. Zhao, *Chem. Commun.*, **2014**, *50*, 2018.
- 16 (a) J. W. Yuan, Y. Z. Li, L. R. Yang, W. P. Mai, P. Mao, Y. M. Xiao, L. B. Qu, *Tetrahedron*, **2015**, *71*, 8178; (b) J. W. Yuan, Y. Z. Li, W. P. Mai, L. R. Yang, L. B. Qu, *Tetrahedron*, **2016**, *72*, 3084; (c) Y. Unoh, K. Hirano, T. Satoh, M. Miura, *Angew. Chem. Int. Ed.*, **2013**, *52*, 12975; (d) Y. R. Chen, W. L. Duan, *J. Am. Chem. Soc.*, **2013**, *135*, 16754.
- 17 (a) X. L. Chen, X. Li, J. W. Yuan, L. B. Qu, S. H. Wang, H. Y. Shi, Y. C. Tang, L. K. Duan, *Tetrahedron*, **2013**, *69*, 4047; (b) V. Kunzmann, E. Bauer, M. N. Wilhelm, *Engl. J. Med.*, **1999**, *340*, 737.
- 18 (a) Y. M. Li, M. Sun, H. L. Wang, Q. P. Tian, S. D. Yang, *Angew. Chem., Int. Ed.*, **2013**, *52*, 3972; (b) J. Ke, Y. Tang, H. Yi, Y. Li, Y. Cheng, C. Liu, A. Lei, *Angew. Chem., Int. Ed.*, **2015**, *54*, 6604; (c) B. Zhang, C. G. Daniliuc, A. Studer, *Org. Lett.*, **2014**, *16*, 250; (d) X. Mi, C. Y. Wang, M. M. Huang, J. Y. Zhang, Y. S. Wu, Y. J. Wu, *Org. Lett.*, **2014**, *16*, 3356.
- 19 X. Qi, S. H. Lee, J. Y. Kwon, Y. M. Kim, S. J. Kim, Y. S. Lee, J. Y. Yoon, *J. Org. Chem.*, **2003**, *68*, 9140.
- 20 S. F. Zhou, D. P. Li, K. Liu, J. P. Zou, O. T. Asekun, *J. Org. Chem.*, **2015**, *80*, 1214.
- 21 H. Krawczyk, Ł. Albrecht, *Synthesis*, **2005**, *17*, 2887.

Graphic Abstract

Silver-catalyzed synthesis of 2-arylvinylphosphonates by cross-coupling of β -nitrostyrenes with *H*-phosphites

Jin-Wei Yuan,* Liang-Ru Yang, Pu Mao, and Ling-Bo Qu*

School of Chemistry & Chemical Engineering, Henan University of Technology; Academician Workstation for Natural Medicinal Chemistry of Henan Province, Zhengzhou 450001, PR China



An efficient protocol for stereoselective synthesis of vinylphosphonates has been developed via AgNO_3 -catalyzed cross-coupling of β -nitrostyrenes with dialkyl *H*-phosphites under mild conditions.